We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To be putting this PIN out, the feasibility study was likely very successful:
“Following a feasibility study (‘P1’), the initiation of targeted pilot studies are proposed as the next step in mobilising mass spectrometry for Covid-19 testing.”
RNSes are important but most important thing is that phase 1 must have gone well because the Government are not only pursuing phase 2 but have gained enough confidence to lay out the plan beyond that all the way to what the PIN describes as industrial scale rollout.
The PIN seems to suggest that phase 1 is complete. Phase 1 is the feasibility study. An RNS may be issued on monday to notify us of the result. Phase 2 clinical validation takes 4 weeks but may not complete until early January since the PIN itself refers to rhe need to first garner goods and services for it,, which might take a couple of weeks or so. However, company has been collecting its own data and I would not be surprised if that is released via RNS in early December.
The below comment from MAP CSO suggests that theirs may not be as good as our BAMs test, well at least not as good as we hope ours will be.
Prof Iles, who is chief scientific officer at MAP Sciences in Bedford suggests the test could be run quickly, cheaply and regularly to rule out Covid-19, or indicate its presence. Further more specific PCR testing could then be carried out if required on those who test positive.
https://www.cambridgeindependent.co.uk/news/could-this-2-50-gargle-test-developed-in-cambridge-be-the-solution-to-covid-19-testing-challenge-9125385/
I'm convinced there'll be an RNS in the next 3 working days which will update on Bams and lft.
We've had a decent rise this week but knowing how this sp moves, I think we could also see a decent rise Monday and Tuesday next week. Just a hunch
1pm RNS possible ? If not we will have to wait until next week.
“ Avacta continues to work actively with the UK government's CONDOR programme to clinically evaluate the coronavirus BAMS assay in order to obtain regulatory approval for diagnostic use. Avacta and Adeptrix are in discussions with mass spectrometer manufacturers with a view to establishing commercial partnerships to market the research use and diagnostic products.”
This is really encouraging. Thanks for your research.
If you can be bothered I recommend you give Bruker a call as I just did.
They will tell you they expect to roll this out in January when it will be for sale.
Afamaman thanks
Bubba - the MMAPp product is not ready. I think it is probably just us at this point and we have passed P1 which is the feasibility study. P2 is the clinical validation which takes 4 more weeks. We should get an RNS then which will give performance figures
Market completely missing the significance of this. Classic retail led share focussing on a single event (LFD 10k rns) whilst missing the cracking sunset going on behind....
Are there any other mass spec products going through validation that anyone knows of??
Is this BOOM 2.0 Poundcake?
Exactly, first real test for affimers in public - passed!
Everyone remembers that slide from Al...
Just wait til we can ship it to the USA
WOW
What did you do Poundcake? :-)
I’d like to see Alistair say a few words about this surely moving to the next stage is newsworthy
Mains pros are that its a lot cheaper by a factor of 4 or 5 than PCR and that it can be used as a prognostic tool as well.
The bid is for a market engagement event.
The workflow of the ms programme mentioned in bid is 4 weeks clinical validation followed by 12 weeks scale validation followed by 4 weeks for NHS scale up. So if all goes well BAMS should be operating at high scale in NHS by April. But it should be bringing in decent revenue by december end through its use for scale validation, assuming the initial clinical validation goes well
there is general importance to this, as it showcases the potential of affimers for covid testing, and that Avacta can and will bring their products to the market.
Or is this FOMO regarding a midday RNS? Will be interesting to see direction of travel immediately after 12!
Not yet phantom... but soon....
Go on poundlake say it'BREAKOUT'
Imagine being able to see to the ENTIRE USA ‘here is a highly accurate, fast cheap alternative to PCR’ to use on every mass spec machine.
Flogged by our US counterpart to Biden and Co.
It’s huge.
Thanks @ Poundcake that does sound exciting perhaps they are making room for our mass spec machines in those new Government super labs :)
@DaAaronizer , Mass spec can be used on existing equipment such as those in hospitals etc. No need for specialist machines so the market is absolutely massive. IMO BAMS will be massive as it can be adopted globally, and being with our partner, we'll get into USA easily.
Al believes it will be gold standard, so no reason why this won't be the #1 test globally with the sheer ease of rollout